Taking stock of the drug industry, from the lab to the medicine chestFebruary 7, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Craig F. Walker/The Boston Globe STAT+ | Angry at Vertex pricing of cystic fibrosis drugs, families in four countries seek to override patents Families and activists are petitioning four governments to make generic versions of expensive Vertex cystic fibrosis drugs accessible. By Ed Silverman STAT+ | Pharma loses a court battle in its bid to block states from importing drugs from Canada A federal judge has tossed a lawsuit that sought to prevent state governments from importing medicines from Canada. By Ed Silverman STAT+ | Former Sen. Richard Burr to join health care practice at law and lobbying firm Former Sen. Richard Burr is the latest participant in Washington's revolving door between policymakers and industry. By Rachel Cohrs J. Scott Applewhite/AP Senators probe telehealth companies for tracking and monetizing sensitive health data A bipartisan group of senators is probing the health data sharing practices of telehealth companies Cerebral, Monument, and Workit Health. By John Wilkerson STAT+ | Chinese DNA giant's U.S. affiliate looks to rival Illumina, touting $100 genome and high-power sequencers The firm plans to launch sequencers it says can decode DNA in larger amounts — and at lower costs — than any instrument on the market. By Jonathan Wosen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments